Who knows what these sp fluctuations mean? Just the short term day traders taking their winnings or losses, or maybe some other investors losing their nerve just before the phase 2 trials begin. The important point is that phase 2 clinical trials are about to start. There is risk associated with this of course, but three years of laboratory work on PPL-1 and one year of phase 1 tests on humans give us confidence. At the present sp the company is basically being valued for little more than its Epichem unit, which is going well. Cheers
Ann: Appendix 4C Quarterly Report & Brief Company Update-PAA.AX, page-35
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
-0.010(4.26%) |
Mkt cap ! $89.08M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 22.0¢ | $170.5K | 749.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34313 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 24444 | 2 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
22.5¢ |
Change
-0.010 ( 6.25 %) |
||||
| Open | High | Low | Volume | ||
| 23.0¢ | 23.0¢ | 22.0¢ | 246904 | ||
| Last updated 15.57pm 14/06/2024 ? | |||||
| PAA (ASX) Chart |